In this study,metabolomic approaches were utilized to enhance the understanding of aroma characteristics,functional components,and nutritional variations in Mizuna at different growth stages.The analysis focused on ev...In this study,metabolomic approaches were utilized to enhance the understanding of aroma characteristics,functional components,and nutritional variations in Mizuna at different growth stages.The analysis focused on evaluating the profiles of volatile and non-volatile metabolites in Mizuna microgreens(MM)and Mizuna baby greens(MBG),with particular attention to their types and quantities.A comprehensive analysis identified 643 volatile and 1416 non-volatile metabolites,among which 132 volatile and 597 non-volatile differential metabolites were recognized as key metabolites associated with Mizuna at various maturity stages.Notably,16 glucosinolates exhibited significant differential expression between MM and MBG.Subsequently,a network pharmacology analysis was conducted to explore the potential therapeutic targets and pathways associated with the bioactive constituents relevant to type 2 diabetes mellitus(T2DM)and obesity(OB),as identified through the metabolomic analysis.Through this network pharmacology analysis,10 core targets and their corresponding 24 bioactive compounds,including 4 flavonoids,4 phenolic acids,and 4 lignans and coumarins,were identified.Combined with molecular docking validation,it was predicted that the active constituents of Mizuna exhibit a strong affinity for their relevant targets in the context of T2DM and OB,suggesting potential therapeutic effects.We provide a theoretical framework for the application of MM and MBG as plant-based functional foods and medicinal food homology plants,characterized by their distinct flavor profiles,nutritional content,and healthpromoting properties.Furthermore,it provides novel insights by integrating foodomics and network pharmacology to advance the development of functional foods and disease treatment strategies.展开更多
基金supported by the Youth Science and Technology Talent Innovation Program of Lanzhou City(2023-QN-58)the Youth Supervisor Foundation of Gansu Agricultural University(GAU-QDFC-2024-11)+1 种基金the Gansu Provincial Major Science and Technology Project(22ZD6NA009)the Research Program Sponsored by the State Key Laboratory of Aridland Crop Science of China,Gansu Agricultural University,China(GSCS-2020-5).
文摘In this study,metabolomic approaches were utilized to enhance the understanding of aroma characteristics,functional components,and nutritional variations in Mizuna at different growth stages.The analysis focused on evaluating the profiles of volatile and non-volatile metabolites in Mizuna microgreens(MM)and Mizuna baby greens(MBG),with particular attention to their types and quantities.A comprehensive analysis identified 643 volatile and 1416 non-volatile metabolites,among which 132 volatile and 597 non-volatile differential metabolites were recognized as key metabolites associated with Mizuna at various maturity stages.Notably,16 glucosinolates exhibited significant differential expression between MM and MBG.Subsequently,a network pharmacology analysis was conducted to explore the potential therapeutic targets and pathways associated with the bioactive constituents relevant to type 2 diabetes mellitus(T2DM)and obesity(OB),as identified through the metabolomic analysis.Through this network pharmacology analysis,10 core targets and their corresponding 24 bioactive compounds,including 4 flavonoids,4 phenolic acids,and 4 lignans and coumarins,were identified.Combined with molecular docking validation,it was predicted that the active constituents of Mizuna exhibit a strong affinity for their relevant targets in the context of T2DM and OB,suggesting potential therapeutic effects.We provide a theoretical framework for the application of MM and MBG as plant-based functional foods and medicinal food homology plants,characterized by their distinct flavor profiles,nutritional content,and healthpromoting properties.Furthermore,it provides novel insights by integrating foodomics and network pharmacology to advance the development of functional foods and disease treatment strategies.
